Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene

Yixi Chen, Karamjit Singh Dolt, Marco Kriek, Terry Baker, Patrick Downey, Nicola J Drummond, Maurice A Canham, Ammar Natalwala, Susan Rosser, Tilo Kunath

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

An emerging treatment for Parkinson's disease (PD) is cell replacement therapy. Authentic midbrain dopaminergic (mDA) neuronal precursors can be differentiated from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs). These laboratory-generated mDA cells have been demonstrated to mature into functional dopaminergic neurons upon transplantation into preclinical models of PD. However, clinical trials with human fetal mesenchephalic cells have shown that cell replacement grafts in PD are susceptible to Lewy body formation suggesting host-to-graft transfer of α-synuclein pathology. Here we have used CRISPR/Cas9n technology to delete the endogenous SNCA gene, encoding for α-synuclein, in a clinical-grade hESC line to generate SNCA+/- and SNCA-/- cell lines. These hESC lines were first differentiated into mDA neurons, and then challenged with recombinant α-synuclein pre-formed fibrils (PFFs) to seed the formation for Lewy-like pathology as measured by phosphorylation of serine-129 of α-synuclein (pS129-αSyn). Wild-type neurons were fully susceptible to the formation of protein aggregates positive for pS129-αSyn, while SNCA+/- and SNCA-/- neurons exhibited significant resistance to the formation of this pathological mark. This work demonstrates that reducing or completely removing SNCA alleles by CRISPR/Cas9n-mediated gene editing confers a measure of resistance to Lewy pathology. This article is protected by copyright. All rights reserved.

Original languageEnglish
Number of pages15
JournalEuropean Journal of Neuroscience
Early online date25 Nov 2018
Publication statusE-pub ahead of print - 25 Nov 2018

Keywords / Materials (for Non-textual outputs)

  • hESCs
  • dopaminergic neurons
  • CRISPR/Cas9n
  • synucleinopathy
  • disease-resistant


Dive into the research topics of 'Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene'. Together they form a unique fingerprint.

Cite this